SEC Form 4 · accession 0001213900-26-075738
Inmune Bio, Inc. · INMB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Juda
Director
Period of report
Jul 2, 2026
Accepted (ET)
Jul 7, 2026 · 7:01 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001711754
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 2, 2026 | M | 14,801 | $1.40 | A | 86,404 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Purchase Warrant | $1.40 | Jul 2, 2026 | X | 14,801 | D | Jul 2, 2026 | Dec 31, 2027 | Common Stock | 14,801 | 14,802 | D |
Explanation of responses
- F1Represents 14,801 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person. The Reporting Person and other holders of common stock purchase warrants previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the "April 2024 Warrants"), entered into a warrant inducement offer letter agreement with the Issuer (the "Inducement Letter"). Pursuant to the Inducement Letter, the Reporting Person agreed to exercise, for cash, 14,801 April 2024 Warrants, representing 50% of the April 2024 Warrants held by it, and agreed to purchase 14,801 shares of common stock at a reduced exercise price of $1.40 in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised, from June 30, 2026, to December 31, 2027.